文献库，生知库 | 链接生命科学的每一步

日期影响因子

Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period

在日本2型糖尿病患者中，伊美格列明联合胰岛素单药治疗的疗效和安全性（TIMES 3）：一项随机、双盲、安慰剂对照的3期临床试验，并设有36周的开放标签扩展期

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14642

Reilhac, Caroline; Dubourg, Julie; Thang, Carole; Grouin, Jean-Marie; Fouqueray, Pascale; Watada, Hirotaka

免疫/内分泌

发表日期：2022

文献求助收藏

Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial

在日本2型糖尿病患者中，伊美格列明单药治疗或与现有降糖药物联合治疗的长期安全性和有效性（TIMES 2）：一项为期52周、开放标签、多中心3期临床试验

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14613

Dubourg, Julie; Fouqueray, Pascale; Quinslot, Damien; Grouin, Jean-Marie; Kaku, Kohei

发表日期：2022

文献求助收藏

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects

伊美格列明在白种人和日本健康受试者中的药代动力学

期刊:Clinical Drug Investigation

影响因子:2.7

doi:10.1007/s40261-022-01181-3

Fouqueray, Pascale; Chevalier, Clémence; Bolze, Sébastien

发表日期：2022

文献求助收藏

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

针对2型糖尿病患者的伊美格列明II期临床试验表明，该药物对胰岛素分泌和敏感性有影响。

期刊:Endocrinology, Diabetes and Metabolism

影响因子:2.6

doi:10.1002/edm2.371

Theurey, Pierre; Thang, Carole; Pirags, Valdis; Mari, Andrea; Pacini, Giovanni; Bolze, Sébastien; Hallakou-Bozec, Sophie; Fouqueray, Pascale

免疫/内分泌

发表日期：2022

文献求助收藏

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.

伊美格列明降低乳酸性酸中毒风险：与二甲双胍的比较

期刊:Physiological Reports

影响因子:1.9

doi:10.14814/phy2.15151

Theurey Pierre, Vial Guillaume, Fontaine Eric, Monternier Pierre-Axel, Fouqueray Pascale, Bolze SÃ©bastien, Moller David E, Hallakou-Bozec Sophie

发表日期：2022

文献求助收藏

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

直接激活AMP激酶对胰岛素抵抗和非酒精性脂肪肝患者的药效学影响：一项1b期研究

期刊:Cell Reports Medicine

影响因子:10.6

doi:10.1016/j.xcrm.2021.100474

Fouqueray, Pascale; Bolze, Sebastien; Dubourg, Julie; Hallakou-Bozec, Sophie; Theurey, Pierre; Grouin, Jean-Marie; Chevalier, Clémence; Gluais-Dagorn, Pascale; Moller, David E; Cusi, Kenneth

免疫/内分泌

发表日期：2021

文献求助收藏

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial

伊美格列明治疗日本2型糖尿病患者的疗效和安全性：一项为期24周的随机、双盲、安慰剂对照、剂量范围探索的2b期试验

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14285

Dubourg, Julie; Ueki, Kohjiro; Grouin, Jean-Marie; Fouqueray, Pascale

发表日期：2021

文献求助收藏

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

伊美格列明的作用机制：一种治疗2型糖尿病的新型药物

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14277

Hallakou-Bozec, Sophie; Vial, Guillaume; Kergoat, Micheline; Fouqueray, Pascale; Bolze, Sébastien; Borel, Anne-Laure; Fontaine, Eric; Moller, David E

发表日期：2021

文献求助收藏

Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

氘稳定化的(R)-吡格列酮(PXL065)是吡格列酮在非酒精性脂肪性肝炎(NASH)中发挥疗效的关键成分，但其对过氧化物酶体增殖物激活受体γ(PPARγ)的活性很低或几乎没有。

期刊:Hepatology Communications

影响因子:4.6

doi:10.1002/hep4.1723

Jacques, Vincent; Bolze, Sébastien; Hallakou-Bozec, Sophie; Czarnik, Anthony W; Divakaruni, Ajit S; Fouqueray, Pascale; Murphy, Anne N; Van der Ploeg, Lex H T; DeWitt, Sheila

发表日期：2021

文献求助收藏